20/20 Biolabs (AIDX) and Its Peers Head-To-Head Contrast

20/20 Biolabs (NASDAQ:AIDX) is one of 237 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its competitors? We will compare 20/20 Biolabs to related companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares 20/20 Biolabs and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
20/20 Biolabs	$2.05 million	-$3.74 million	-1.99
20/20 Biolabs Competitors	$20.51 billion	$280.23 million	1.38

20/20 Biolabs’ competitors have higher revenue and earnings than 20/20 Biolabs. 20/20 Biolabs is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares 20/20 Biolabs and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
20/20 Biolabs Competitors	-5.33%	-138.00%	-0.38%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for 20/20 Biolabs and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1	0	1	0	2.00
20/20 Biolabs Competitors	1760	7504	12948	783	2.55

20/20 Biolabs currently has a consensus target price of $5.00, indicating a potential upside of 797.67%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.97%. Given 20/20 Biolabs’ higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than its competitors.

Institutional and Insider Ownership

57.6% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 15.3% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

20/20 Biolabs competitors beat 20/20 Biolabs on 7 of the 12 factors compared.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD.